Linking pages
- RSV vaccine to protect infants gets green light from FDA advisors | Ars Technica https://arstechnica.com/health/2023/05/rsv-vaccine-to-protect-infants-gets-green-light-from-fda-advisors/ 2 comments
- Intel’s oft-delayed “Sapphire Rapids” Xeon CPUs are finally coming in early 2023 | Ars Technica https://arstechnica.com/information-technology/2022/11/intels-oft-delayed-sapphire-rapids-xeon-cpus-are-finally-coming-in-early-2023/ 0 comments
- RSV vaccine for older adults is 84% effective, Moderna says | Ars Technica https://arstechnica.com/science/2023/01/rsv-vaccine-for-older-adults-is-84-effective-moderna-says/ 0 comments
Linked pages
- Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis - The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00478-0/fulltext 6 comments
- Intel’s oft-delayed “Sapphire Rapids” Xeon CPUs are finally coming in early 2023 | Ars Technica https://arstechnica.com/information-technology/2022/11/intels-oft-delayed-sapphire-rapids-xeon-cpus-are-finally-coming-in-early-2023/ 0 comments
Related searches:
Search whole site: site:arstechnica.com
Search title: Why Pfizer’s RSV vaccine success is a big deal, decades in the making | Ars Technica
See how to search.